Back

Intermittent levosimendan therapy and survival outcomes in advanced heart failure: insights from a real-world single-centre study

19 May 2025 (14:20 - 15:40)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (2) Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Catarina Gregorio

Centro Hospitalar Universitário Lisboa Norte, Lisbon (Portugal)

5 More presentations in this session

Presentation thumbnail
Which treatment attributes do patients with transthyretin amyloid cardiomyopathy value most?
Ms A. Carr (Hagersville, CA)
Abstract Slides Video
Presentation thumbnail
Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study
Doctor E. Haakansson (Umea, SE)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and outcomes in a cohort of patients starting treatment with vericiguat in the US.
Doctor A. Michel (Basel, CH)
Abstract Slides Video
Presentation thumbnail
The care-gap for women living with heart failure
Doctor O. Graham (Craigavon, GB)
Abstract Slides Video
Presentation thumbnail
Ambulatory blood pressure monitoring reveals true significant hypotension in stable HF patients; Is this an overlooked issue?
Doctor G. Bruno (Limerick, IE)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (2)

The Event

Event poster

Heart Failure 2025

19 May 2025 14:20 CET
You may be interested in
thumbnail
Congress Presentation
Real-world impact of intermittent levosimendan on survival, hospitalizations, and healthcare costs in advanced heart failure
thumbnail
Congress Presentation
Intermittent levosimendan in advanced palliative heart failure improves quality of life and reduces heart failure decompensations: a single center-experience
thumbnail
Congress Presentation
The role of intermittent levosimendan infusions in patients with advanced heart failure: is it enough?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources